Abbott launches Navitor Vision Valve in India for high-risk aortic stenosis patients

Navitor Vision enhances visibility and precision in TAVI procedures, offering a less invasive alternative to surgical aortic valve replacement
Abbott launches Navitor Vision Valve in India for high-risk aortic stenosis patients

Abbott, a global healthcare company, has announced the launch of Navitor Vision in India for patients with symptomatic severe aortic stenosis who are at high or extreme surgical risk. The device is the latest iteration of Abbott’s Navitor transcatheter aortic valve implantation/replacement (TAVI/TAVR) system.

Navitor Vision introduces three large Vision markers to enhance visibility and simplify valve deployment during TAVI procedures. These markers assist interventionists in implanting the device more accurately and make the valve easier to see during the procedure.

“For some people, open-heart surgery is considered a high-risk procedure due to the potential complications stemming from age, frailty or having multiple other diseases or conditions,” said Neeraj Singh, country manager for Abbott’s structural heart business in India. “TAVI serves as a less invasive alternative to surgical aortic valve replacement and can reduce symptoms and improve the life expectancy of patients with this condition. Abbott’s Navitor Vision valve is an important addition to our range of treatments for structural heart issues, particularly for heart valve disease, and offers hope to people who may not have other treatment choices.”

The Navitor Vision valve is available in different sizes to accommodate heart openings (annulus) ranging from 19 mm to 27 mm, ensuring it fits most patients in need of TAVI. It features a dynamic sealing cuff designed to minimise blood leakage back to the heart.

The valve is implanted using Abbott’s FlexNav delivery system, which has a slim design to treat patients with blood vessels as small as 5.0 mm. The FlexNav catheter is designed to handle various aortic anatomies, ensuring stable and accurate valve placement.

Clinical studies have demonstrated Navitor’s effectiveness, showing a large opening area and low mean pressure gradient across the valve, indicating efficient blood flow with minimal resistance. The valve’s large frame cells facilitate easy access to coronary arteries, enabling future treatment for coronary artery disease.

The launch of Navitor Vision in India is set to expand treatment options for patients with severe aortic stenosis, providing a less invasive alternative and enhancing clinical outcomes.

AbbottNavitor Vision ValveTranscatheter Aortic Valve Implantationtranscatheter aortic valve replacement
Comments (0)
Add Comment